GDC-0853
Sponsors
Genentech, Inc., Hoffmann-La Roche
Conditions
Healthy ParticipantsHealthy VolunteerHealthy VolunteersLupus Erythematosus, SystemicLymphocytic Leukemia, Chronic, Diffuse Large B-Cell LymphomaRheumatoid ArthritisSystemic Lupus ErythematosusUrticaria
Phase 1
A Study of GDC-0853 in Patients With Resistant B-Cell Lymphoma or Chronic Lymphocytic Leukemia.
CompletedNCT01991184
Start: 2013-12-16End: 2022-03-08Updated: 2022-06-21
Effect of Food, Rabeprazole, Methotrexate and Formulation on the Pharmacokinetics (PK) of GDC-0853 and the Effect of GDC-0853 on the PK of Methotrexate in Healthy Subjects
CompletedNCT02699710
Start: 2015-09-03End: 2016-05-26Updated: 2020-03-02
A Drug-Drug Interaction Study Between GDC-0853 and Midazolam, Itraconazole, Rosuvastatin, and Simvastatin
CompletedNCT03174041
Start: 2017-04-18End: 2017-06-23Updated: 2019-09-24
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GDC-0853 in Healthy Japanese and Caucasian Participants
CompletedNCT03188783
Start: 2017-01-24End: 2017-08-09Updated: 2019-08-07
A Study to Investigate the Effect of Formulation, Food, and Rabeprazole on the Pharmacokinetics (PK) of GDC-0853 in Healthy Participants
CompletedNCT03290703
Start: 2017-04-18End: 2018-10-25Updated: 2019-09-11
Phase 2
Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)
CompletedNCT02833350
Start: 2016-09-09End: 2018-07-02Updated: 2020-06-12
A Study of the Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus
CompletedNCT02908100
Start: 2017-01-19End: 2019-07-16Updated: 2024-05-08
A Study to Evaluate the Long-Term Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Rheumatoid Arthritis Enrolled in Study GA29350
CompletedNCT02983227
Start: 2016-11-30End: 2019-07-17Updated: 2020-08-03
A Study of GDC-0853 in Participants With Refractory Chronic Spontaneous Urticaria (CSU).
CompletedNCT03137069
Start: 2017-05-26End: 2019-10-25Updated: 2020-09-29
An Extension Study of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus
TerminatedNCT03407482
Start: 2018-01-09End: 2019-11-20Updated: 2020-12-19
A Study to Evaluate the Long-term Safety and Efficacy of Fenebrutinib in Participants Previously Enrolled in a Fenebrutinib Chronic Spontaneous Urticaria (CSU) Study
TerminatedNCT03693625
Start: 2018-09-27End: 2019-10-23Updated: 2020-09-25